UNLOCK LDL-C CONTROL WITH A DEMONSTRATED SAFETY
PROFILE. ADD NEXLIZET.

Incidence of most common ARs generally comparable to placebo1

ARs occurring in ≥3% of patients in the NEXLIZET group in a 4-arm, 12-week,
randomized, double-blind, placebo-controlled, parallel group, factorial trial2,3

Adverse reaction NEXLIZET
(n=85)
% (n)
Bempedoic acid
(n=88)
% (n)
Ezetimibe
(n=86)
% (n)
Placebo
(n=41)
% (n)
Urinary tract infection 5.9%
(5)
3.4%
(3)
2.3%
(2)
2.4%
(1)
Nasopharyngitis 4.7%
(4)
6.8%
(6)
4.7%
(4)
0.0%
(0)
Constipation 4.7%
(4)
0.0%
(0)
2.3%
(2)
0.0%
(0)
Back pain 3.5%
(3)
3.4%
(3)
2.3%
(2)
4.9%
(2)
Fatigue 3.5%
(3)
2.3%
(2)
1.2%
(1)
0.0%
(0)
Upper respiratory tract infection 3.5%
(3)
1.1%
(1)
0.0%
(0)
0.0%
(0)
Blood creatinine increased 3.5%
(3)
1.1%
(1)
0.0%
(0)
0.0%
(0)
Blood uric acid increased 3.5%
(3)
1.1%
(1)
0.0%
(0)
0.0%
(0)
Bronchitis 3.5%
(3)
0.0%
(0)
3.5%
(3)
0.0%
(0)

DISCONTINUATION RATES DUE TO ARs2:
NEXLIZET: 8%; bempedoic acid: 10%; ezetimibe: 12%; placebo: 5%

  • Most common reason for NEXLIZET treatment discontinuation was oral discomfort (NEXLIZET: 2%; placebo: 0%)

Incidence of ARs occurring in pivotal trials of bempedoic acid or ezetimibe that did not occur at a significant rate in the pivotal trial of NEXLIZET above2

  • Pivotal trials for bempedoic acid: ARs occurring in ≥2% of patients with ASCVD and HeFH using bempedoic acid* (and more frequently than placebo) included muscle spasms (bempedoic acid: 3.6%; placebo: 2.3%), hyperuricemia† (3.5%; 1.1%), abdominal pain or discomfort (3.1%; 2.2%), pain in extremity (3.0%; 1.7%), anemia (2.8%; 1.9%), and elevated liver enzymes§ (2.1%; 0.8%)
  • Pivotal trials for ezetimibe: ARs occurring in ≥2% of patients using ezetimibe (and at an incidence greater than placebo), regardless of causality, included diarrhea (ezetimibe: 4.1%; placebo: 3.7%), arthralgia (3.0%; 2.2%), sinusitis (2.8%; 2.2%), pain in extremity (2.7%; 2.5%), and influenza (2.0%; 1.5%)

Please see Important Safety Information, including Contraindications, and Warnings and Precautions about Hyperuricemia and Tendon Rupture, below.

*Patients received bempedoic acid 180 mg orally once daily plus maximally tolerated statin therapy alone or in combination with other lipid-lowering therapies.2

Included patients with hyperuricemia and patients with increased blood uric acid.2

Included patients with abdominal pain, upper abdominal pain, lower abdominal pain, and abdominal discomfort.2

§Included patients with increased AST, increased ALT, increased hepatic enzyme, and increased liver function test.2

LDL-C=low-density lipoprotein cholesterol; AR=adverse reaction; ASCVD=atherosclerotic cardiovascular disease; HeFH=heterozygous familial hypercholesterolemia; AST=aspartate aminotransferase; ALT=alanine aminotransferase.

References: 1. Data on file. CSR 1002-053. January 2019. 2. NEXLIZET. Prescribing information. ESPERION Therapeutics, Inc.; 11/2020. 3. Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593-603.


SEE NEXLIZET PATIENT TYPES